Gastrointestinal Vomiting, diarrhea, nausea, constipation, abdominal pain, upper abdominal pain, dry mouth, dysgeusia, dyspepsia, flatulence, tongue discoloration may occur. Endocrine The drug may cause adrenal insufficiency so the level of the adrenocortical hormones should be monitored while taking it. Oral<unk>  at a dosage range of 400 to 2,000 mg/day has been found to result in a rate of gynecomastia of 21%. Liver In July 2013, the U.S. Food and Drug Administration (FDA) issued a warning that taking<unk>  by mouth can cause severe liver injuries and adrenal gland problems: adrenal insufficiency and worsening of other related to the gland conditions. It recommends oral tablets should not be a first-line treatment for any fungal infection. It should be used for the treatment of certain fungal infections, known as endemic mycoses, only when alternative antifungal therapies are not available or tolerated. As contraindication it should not be used in people with acute or chronic liver disease. Hypersensitivity Anaphylaxis after the first dose may occur. Other cases of hypersensitivity include urticaria. Topical formulations The topical formulations have not been associated with liver damage, adrenal problems, or drug interactions. These formulations include creams, shampoos, foams, and gels applied to the skin, unlike the<unk>  tablets, which are taken by mouth. Pregnancy<unk>  is categorized as pregnancy category C in the US. Research in animals has shown it to cause teratogenesis when administered in high doses. A subsequent trial in Europe failed to show a risk to infants of mothers receiving<unk> .
Ketoconazole
Levoketoconazole
Itraconazole
Sertaconazole
Miconazole
Terbinafine
Efinaconazole
Posaconazole